A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes (Q44683742)

5 December 2017

A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes (English)

1 reference

5 December 2017

1 reference

placebo-controlled trial

1 reference

3

E Magnus Ohman

1 reference

5 December 2017

1

Matthew T Roe

1 reference

5 December 2017

6

Alan Storrow

1 reference

5 December 2017

Robert H Christenson

2

1 reference

5 December 2017

Raymond Bahr

4

1 reference

5 December 2017

Francis M Fesmire

5

1 reference

5 December 2017

Michael Mollod

7

1 reference

5 December 2017

W Frank Peacock

8

1 reference

5 December 2017

Jeffrey A Rosenblatt

9

1 reference

5 December 2017

Hongqiu Yang

10

1 reference

5 December 2017

Elizabeth S Fraulo

11

1 reference

5 December 2017

James W Hoekstra

12

1 reference

5 December 2017

W Brian Gibler

13

1 reference

5 December 2017

EARLY Investigators

14

1 reference

5 December 2017

Emergency Medicine Cardiac Research and Education Group

15

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

5 December 2017

American Heart Journal

1 reference

5 December 2017

146

1 reference

5 December 2017

6

1 reference

5 December 2017

993-998

1 reference

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

5 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice g

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

Angiographic findings in patients with refractory unstable angina according to troponin T status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

Multisite study of a second generation whole blood rapid assay for cardiac troponin T.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

Temporal creatine kinase curves in acute myocardial infarction. Implications of a good empiric fit with the log-normal function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppressio

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900517-9

10.1016/S0002-8703(03)00517-9

7 January 2021

Identifiers

DOI

1 reference

5 December 2017

1 reference